UPLOAD Filing
TANDEM DIABETES CARE INC
Date: May 13, 2025 · CIK: 0001438133 · Accession: 0000000000-25-005081
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 001-36189
Referenced dates: March 25, 2025
Letter
Re: TANDEM DIABETES CARE INC Form 10-K for the Year Ended December 31, 2024 Form 8-K Filed April 30, 2025 Form 8-K Filed February 26, 2025 File No. 001-36189 Dear Leigh Vosseller:
May 13, 2025
Leigh Vosseller Executive Vice President, Chief Financial Officer and Treasurer TANDEM DIABETES CARE INC 12400 High Bluff Drive San Diego, California 92130
We have reviewed your April 4, 2025 response to our comment letter and have the following comments.
Please respond to this letter within ten business days by providing the requested information or advise us as soon as possible when you will respond. If you do not believe a comment applies to your facts and circumstances, please tell us why in your response.
After reviewing your response to this letter, we may have additional comments. Unless we note otherwise, any references to prior comments are to comments in our March 25, 2025 letter.
Form 8-K Filed April 30, 2025 Exhibit 99.1, page 7
1. We note your non-GAAP measures for the three months ended March 31, 2025 include an adjustment for acquired In-Process Research and Development (IPR&D) expenses recorded in conjunction with the revised AMF Medical share asset acquisition. Please tell us what consideration you gave to the guidance in Question 100.01 of the Non-GAAP Financial Measures Compliance and Disclosure Interpretation in determining it was appropriate to include this adjustment. Please specifically address why these expenses would not be considered normal, recurring, cash operating expenses necessary to operate your business. May 13, 2025 Page 2
Form 8-K Filed February 26, 2025 Exhibit 99.1, page 4
2. We are continuing to evaluate your response to comment 1 in our letter dated March 25, 2025 and may have additional comments. Please contact Nudrat Salik at 202-551-3692 or Jeanne Baker at 202-551-3691 if you have questions regarding comments on the financial statements and related matters.
Sincerely,
Division of
Corporation Finance
Office of Industrial
Applications and
Services
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> May 13, 2025 Leigh Vosseller Executive Vice President, Chief Financial Officer and Treasurer TANDEM DIABETES CARE INC 12400 High Bluff Drive San Diego, California 92130 Re: TANDEM DIABETES CARE INC Form 10-K for the Year Ended December 31, 2024 Form 8-K Filed April 30, 2025 Form 8-K Filed February 26, 2025 File No. 001-36189 Dear Leigh Vosseller: We have reviewed your April 4, 2025 response to our comment letter and have the following comments. Please respond to this letter within ten business days by providing the requested information or advise us as soon as possible when you will respond. If you do not believe a comment applies to your facts and circumstances, please tell us why in your response. After reviewing your response to this letter, we may have additional comments. Unless we note otherwise, any references to prior comments are to comments in our March 25, 2025 letter. Form 8-K Filed April 30, 2025 Exhibit 99.1, page 7 1. We note your non-GAAP measures for the three months ended March 31, 2025 include an adjustment for acquired In-Process Research and Development (IPR&D) expenses recorded in conjunction with the revised AMF Medical share asset acquisition. Please tell us what consideration you gave to the guidance in Question 100.01 of the Non-GAAP Financial Measures Compliance and Disclosure Interpretation in determining it was appropriate to include this adjustment. Please specifically address why these expenses would not be considered normal, recurring, cash operating expenses necessary to operate your business. May 13, 2025 Page 2 Form 8-K Filed February 26, 2025 Exhibit 99.1, page 4 2. We are continuing to evaluate your response to comment 1 in our letter dated March 25, 2025 and may have additional comments. Please contact Nudrat Salik at 202-551-3692 or Jeanne Baker at 202-551-3691 if you have questions regarding comments on the financial statements and related matters. Sincerely, Division of Corporation Finance Office of Industrial Applications and Services </TEXT> </DOCUMENT>